InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:15 August 2023

PETRANHA: This phase I/II study is evaluating how safe and effective a new targeted therapy (AZD5305) when given in combination with new hormonal agents (enzalutamide, abiraterone acetate or darolutamide) in people with metastatic prostate cancerA Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Clinical summary

Summary

Approximately 140 people will be enrolled and screening to ensure that up to approximately 126 evaluate patients can be assigned to study treatments across all three study arms. Eligible participants will be non-randomly assigned two one of three experimental arms. In Experimental Arm 1, participants will receive an oral dose of AZD5305 and oral dose of Enzalutamide once daily. In Experimental Arm 2, participants will receive an oral dose of AZD5305 and an oral dose of Abiraterone Acetate once daily. In Experimental Arm 3, participants will receive an oral dose of AZD5305 once daily and an oral dose of Darolutamide twice daily.

Age

People18 - 130

Phase

I/II

Trial Acronym

PETRANHA

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

AstraZeneca

Scientific Title

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

  • You are able to swallow medication by mouth.
  • You have had a certain type of treatment or surgical procedure.
  • Your cancer has spread to other parts of the body.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more